The Hemogenyx share price is up 1,400% since April. Here’s what you need to know

Looking for a multi-bagger biotech growth stock? The Hemogenyx share price has been flying since the firm launched its Covid-19 project.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Since the Covid-19 pandemic hit, investors have been searching for pharmaceuticals and biotechnology stocks that could hit the big time.

Enter Hemogenyx Pharmaceuticals (LSE: HEMO). For the first few months of 2020, this tiny biotech firm looked like the typical penny stock. It’s been showing no profits, and the Hemogenyx share price was wobbling around a penny or two.

Hemogenyx has been researching blood cancers and autoimmune diseases. Then, in April, the firm announced the start of its Covid-19 project. And the Hemogenyx share price took off. Before I look at the investment case, what’s the technology all about?

Hemogenyx uses humanised mice or, in technical terms, Advanced peripheral blood Hematopoietic Chimera (ApbHC). They “were developed to model blood and autoimmune diseases and to test treatments.”

Covid-19 research

These mice were already being used to research antibodies for use as antiviral therapies. So the leap to Covid-19 seems an obvious one. In the company’s words: “As part of its studies, Hemogenyx will transplant cells from blood samples from patients who are either recovering or have already recovered from Covid-19 into its ApbHC humanized mice. The process will allow the Company’s scientists to recreate a set of anti-SARS-CoV-2 virus antibodies which could be used for the treatment of Covid-19.

Some people react severely to Covid-19 infection, while some experience mild or even no symptoms. And the first stage is to try to find out why.

Hemogenyx share price flying

In the week following the announcement, the Hemogenyx share price soared from 1.83p to 10.8p. That was a quick six-fold increase, and a massive gain since April’s low of 0.95p.

Since then, the shares remained around that level until very recently. On 20 August, the price started to pick up again. And we’ve only had news of a research agreement unrelated to the coronavirus. As I’m writing, I’m looking at a further 24% rise on the day so far. I’m having to change my headline as the hours progress.

Hemogenyx has certainly caught the attention of investors, but I’m very cautious. Some experienced growth investors will see genuine potential here for long-term gains. They’ll understand the attached risks and will be prepared to take them on. After all, just one multi-bagger in every five or six punts can be enough to make some decent money.

But there must also be some ‘get rich quick’ investors chasing the Hemogenyx share price upwards too. And that’s rarely a strategy for success.

More gains to come?

Right now, I have no way of evaluating the chances of Hemogenyx making the big breakthrough. Humanised mice are nothing new in themselves. But I don’t have the expertise to know whether the Hemogenyx ones are especially promising. And there must be a possibility that an effective vaccine could render this research largely obsolete.

And then there’s the current profitless nature of the company, which makes it impossible for me to put a value on it. The share price might be up at 14.5p now (or even higher by the time you read this — or maybe it’s already crashed). But to me it still has all the characteristics of a penny stock, and the Hemogenyx share price looks like a pure gamble.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Will it be too late to buy Nvidia stock in March?

NVIDIA stock is up more than 60% since the start of 2024. Our writer considers whether it might still be…

Read more »

Typical street lined with terraced houses and parked cars
Investing Articles

Why did Direct Line shares just soar 27%?

Direct Line shares have jumped more than a quarter in the course of today's trading session. Our writer explains why…

Read more »

Close-up of British bank notes
Investing Articles

These 2 shares are Dividend Aristocrats. Which should I buy this March?

Our writer likes the business model of this pair of FTSE 100 Dividend Aristocrats. So why would he only consider…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

I bought 49 Unilever shares in June. Here’s what they’re worth today

Harvey Jones bought a modest amount of Unilever shares last summer hoping the stock would soon recover. He's having to…

Read more »

BUY AND HOLD spelled in letters on top of a pile of books. Alongside is a piggy bank in glasses. Buy and hold is a popular long term stock and shares strategy.
Investing Articles

I reckon these shares, potentially 20% undervalued, are Warren Buffett’s type of investment

Oliver Rodzianko thinks Games Workshop is an absolutely stellar investment. As it's potentially undervalued, he reckons Warren Buffett would agree.

Read more »

Calendar showing the date of 5th April on desk in a house
Investing Articles

Great investing habits that can boost my Stocks and Shares ISA

Forget complicated calculations and financial jargon! Our writer uses a few simple habits to build wealth inside his Stocks and…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Why has the St. James’s Place share price crashed 30%, after FY results?

The St. James's Place share price has just fallen off a cliff. What could have gone wrong in 2023 that's…

Read more »

Family in protective face masks in airport
Investing Articles

Here’s how much I’d have if I’d bought 1,000 Rolls-Royce shares 10 years ago

Rolls-Royce shares may be flying high this year but that wasn't always the case. I'm calculating how much I'd have…

Read more »